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Exposure to lead is still an international public
health problem, despite major reductions in
its use in industrial processes in developed
countries (1). The neurotoxic effects of lead in
the fetus, neonate, and infant are well recog-
nized (2). The main reservoir of lead within
the body is the skeleton and, until recently,
lead was considered to be relatively immobile
in this compartment. Recent studies using the
stable lead isotope fingerprinting method in
nonhuman primates (3,4) as well as in
humans (5,6) indicate that lead, like calcium,
is mobilized from the maternal skeleton and
transferred to the fetus and neonate during
pregnancy and lactation. Other times of phys-
iologic stress that could result in additional
release of lead from the skeleton include
menopause (7). In a preliminary assessment of
data from the Third National Health and
Nutritional Examination Survey (NHANES
III), higher blood lead (BPb) levels were
observed in postmenopausal compared with
premenopausal women (3.9 vs. 2.6 µg/dL),
consistent with the increased bone turnover
that occurs during the hormonal changes of
menopause. Moreover, higher BPb levels were
associated with lower bone density in peri-
menopausal women (8). Similar relationships
in BPb and menopause were noted earlier (9).
In a study of 903 women 35–64 years of age
from Mexico City, the highest BPb levels were
observed in women 47–50 years of age, with a
mean difference between pre- and post-
menopausal women of 0.76 µg/dL (10).
These higher blood levels could have signiﬁ-
cant health implications because increased
BPb levels in adults have been correlated with
hypertension (11–16), decreased renal func-
tion (17), impaired neurocognitive function
(18), and Alzheimer disease (19).
Antiresorptive agents that inhibit resorp-
tion in the bone remodeling process may
reduce or even reverse the demineralization
process documented during pregnancy and
lactation, observed in perimenopausal women
(20), and seen in men and women with corti-
costeroid-induced osteoporosis (21). Thus,
these agents may have the additional beneﬁt
of preventing increases in BPb levels com-
monly seen in these life stages. During preg-
nancy, calcium supplementation is associated
with lower BPb levels (22–24), although cal-
cium given alone has not been proven to
reverse the loss of bone mineral density dur-
ing pregnancy (24) or in postmenopausal
subjects (25). In menopausal women, antire-
sorptive agents such as hormone replacement
therapy (HRT) and bisphosphonates are
capable of preventing loss of bone density
(20,25,26). Postmenopausal women taking
HRT have been observed to have signiﬁcantly
higher cortical bone lead concentrations than
those not taking HRT (27). To our knowl-
edge there have been no prospective studies
to document the effect of antiresorptive
agents on BPb levels in healthy adults.
We performed a pilot study of the effect
of a potent bisphosphonate (alendronate)
administered over a 6-month period on BPb
levels and other markers of bone turnover in
healthy pre- and postmenopausal women and
men. The aim of this study was to determine
how BPb isotopes and BPb concentrations
changed in relation to bone remodeling
processes and to changes in bone resorption.
We included males in this study because of
the concerns raised earlier by the U.S.
National Institutes of Health about increased
bone fractures in males (28).
Materials and Methods
Subjects. Subjects in our main group were
immigrants to Australia whose skeletal lead
isotopic composition was different from that
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There has been renewed interest in impacts on physiologic systems in the middle and older age
groups, especially from fractures and hypertension. Increased blood lead (BPb) levels in post-
menopausal females, which are thought to arise from bone demineralization, may also relate to
other health effects including hypertension. Taking advantage of natural differences in lead iso-
tope signature between Australian sources of lead and those from other countries, a 2-year pilot
study was performed in premenopausal and postmenopausal females and male partners in which
the subjects were administered a bisphosphonate, alendronate, for 6 months. The aim of the study
was to determine how lead isotopes and lead concentrations changed in relation to bone remodel-
ing processes. Premenopausal subjects were a woman (and male partner) from Bosnia and two
women from Colombia. The postmenopausal subject was a woman from Russia. Her male partner
and one man from Sri Lanka were included. Multigenerational Australian subjects were 2 peri-
menopausal women and 1 postmenopausal woman. Each subject had blood and urine samples col-
lected for markers of bone turnover and for lead isotope studies monthly for 7–9 months before,
for 3 months during, and for up to 6 months after treatment with alendronate to inhibit bone
resorption. Each subject thus acted as his or her own control. As predicted, there were signiﬁcant
decreases in the lead isotope ratio, 206Pb/204Pb, for the migrant subjects during treatment com-
pared with the pretreatment period (p < 0.01). After cessation of treatment, an increasing isotope
ratio for the postmenopausal subject (and older male partner) occurred later than for pre-
menopausal subjects, indicative of prolonged efﬁcacy of the alendronate for the older subjects. The
average BPb concentrations in migrant subjects decreased by about 20% during the treatment
compared with the pretreatment period (p < 0.01). To our knowledge, these are the ﬁrst BPb con-
centrations reported over monthly to quarterly intervals for environmentally exposed adults over
an extended period. The changes in lead isotopic composition and lead concentration are consis-
tent with a decrease in bone resorption and associated mobilization of lead during alendronate
therapy. Older subjects at risk of fractures may beneﬁt from treatment with antiresorptive therapy,
such as the potent bisphosphonates, with the added bonus of lower release of lead from bones and
thus less risk of the potential adverse health effects of increased BPb levels. Key words: bisphos-
phonate, blood, bone mineral density, bone turnover, isotopes, lead, NTx test. Environ Health
Perspect 110:1017–1023 (2002). [Online 27 August 2002]
http://ehpnet1.niehs.nih.gov/docs/2002/110p1017-1023gulson/abstract.htmlin their current environment. In essence, the
lead isotopic composition or “signature” in
multigenerational Australian residents is dif-
ferent from that in subjects from most other
countries because the historical sources of lead
in Australia are dominated by geologically old
lead (5,6,29). Hence, by monitoring the BPb
isotopes of migrant subjects after arrival in
Australia, it was possible to detect changes in
isotopic composition and BPb concentration
related to mobilization of skeletal lead as was
ﬁrst explored by Manton (30,31).
Premenopausal subjects included two
women from Colombia and a woman and
her male partner from Bosnia. The older
group included a postmenopausal Russian
woman and her male partner and a male from
Sri Lanka. The multigenerational Australian
group included three women—two peri-
menopausal and one postmenopausal—and
one male partner, all who were long-term
Australian residents. The Australian subjects
were included as a comparison with the
migrant subjects but have a more complex
history of HRT.
Protocols. Before commencing any treat-
ment, we collected blood and urine samples
from each subject for measurements of markers
of bone turnover. For the lead isotope measure-
ments, seven to nine blood and urine samples
were collected monthly before alendronate
therapy, monthly during therapy, and on two
occasions 3 and 6 months after discontinuing
the drug therapy. The bone turnover markers
were repeated after 3 months of alendronate
therapy (10 mg/day) and again 3 months after
discontinuing the drug therapy. Each subject
thus acted as his or her own control.
None of the migrant subjects had previ-
ously taken HRT. One perimenopausal
Australian subject (subject 1112) replaced
HRT with alendronate for 6 months during
the treatment period. The postmenopausal
Australian subject (subject 800) took HRT in
addition to alendronate throughout the study.
A questionnaire based on that developed
by the Bone and Mineral Research Program
at the Garvan Institute, and especially focused
on calcium intake, was administered on one
occasion by the cohort coordinator (K.M.) at
the beginning of the study. Any major
changes in dietary intake were examined at
each sampling time point.
Ethics approval was obtained from the
Western Sydney Area Health Service, Human
Research Ethics Committee.
Analytical methods. All sample prepara-
tion was performed in purpose-built low-con-
tamination laboratories (“clean rooms”)
incorporating filtered air intake and laminar
ﬂow hoods. To minimize sample heterogene-
ity, the total blood sample was predigested in
ultrapure concentrated nitric acid and an
aliquot of < 1 g removed to a clean Teflon
vessel. We added a 202Pb spike solution of
known isotopic composition and lead con-
centration (~10 ng/g) to the aliquot to obtain
the concentration of lead and isotopic com-
position of the unknown sample in the one
analysis, the isotope dilution method. 202Pb,
with a half-life of about 3 × 105 years, is not
naturally occurring but is a cyclotron by-
product of preparation of thallium. We fur-
ther separated lead from interfering ions such
as iron and zinc using anion exchange chro-
matography in a bromide medium.
For isotope ratio measurement, we loaded
fractions of the purified lead samples onto a
zone-reﬁned rhenium ﬁlament using the silica
gel technique (a mix of dilute phosphoric acid
and puriﬁed silica gel) and analyzed them for
lead isotope composition (and lead concen-
trations by isotope dilution) on a thermal
ionization mass spectrometer (VG-ISOMASS
54E) (VG Isotopes, Winsford, UK) run in
fully automatic mode. Isotopic ratios were
measured as 208Pb/206Pb, 207Pb/206Pb, and
206Pb/204Pb. Precision estimates on the iso-
topic ratios have been deﬁned by a repetition
of the digestion/lead separation/mass spec-
trometry stages of the same samples of blood,
urine, and water. The estimated precision for
the isotopic ratios is ± 0.2% (2 σ) on the
206Pb/204Pb ratio, ± 0.1% on the 208Pb/206Pb
and 207Pb/206Pb ratios, and ± 3% for the lead
concentration. Data were normalized to the
accepted values of the international standard
NIST SRM 981 (National Institute of
Standards and Technology, Gaithersburg,
MD, USA) by applying a correction factor of
+ 0.08% per atomic mass unit to allow com-
parisons between laboratories. A measure-
ment of the environmental lead acquired by
the sample throughout the entire preparation
analysis procedure was obtained in the form
of a lead blank measurement. The amount of
contamination detected in blanks was gener-
ally around 200 pg for blood. As the blanks
contributed negligibly to the lead in the sam-
ple, no blank corrections were performed.
Biochemical markers of bone turnover.
The NTx test is an enzyme-linked immunosor-
bent assay of urinary cross-linked N-telopep-
tides of type 1 collagen, which are speciﬁc to
bone and are stable in urine (OSTEOMARK,
Ostex International, Seattle, WA, USA).
Clinical studies have demonstrated reductions
in the NTx value during HRT in post-
menopausal women (25) and after treatment
with alendronate (26). Serum measurements
included calcium, phosphate, total alkaline
phosphatase, and osteocalcin. We measured
bone mineral density by dual-energy X-ray
absorptiometry (Norland XR 36 Densitometer)
(Xtron Imaging Inc., Mississauga, Ontario,
Canada) at the lumbar spine, femoral neck, and
wrist on two occasions 12 months apart, one
before alendronate treatment and the other
after treatment. To assess bone density, we used
the T-score, which compares the measured
bone density with that of healthy young adults,
and the Z-score, which compares the measured
bone density of the subject with the average of
persons of the same age. 
Statistical analysis. Using the same statis-
tical methods as described by Gulson et al.
(6), we ﬁtted separate regression lines by least
squares for each subject in each of the three
periods before, during, and after alendronate
therapy. This enabled the comparison of the
average rate of change of blood measurements
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Table 1. Information on subjects.
First BPb Bone mineral density
Country Menopausal Time in concentration Lumbar spine Femoral neck Wrist
Subject of origin Sex/age status Australia (days) (µg/dL) Z T Z T Z T
1101 Bosnia M/54 — 678 3.6 0.9 0.3 0.8 –1.2 0.5 0.3
1102 Bosnia F/44 Pre 678 1.4 2.26 1.51 0.06 –0.72 1.48 1.52
1103 Colombia F/45 Pre 558 3.9 0.1 –0.7 0.8 –0.1 0.1 0.1
1104 Colombia F/46 Pre 396 1.4 0.02 –0.79 0.18 –0.67 –0.72 –0.68
1105 Bulgaria M — 27 10.6 NM NM NM NM NM NM
1106 Bulgaria F Post 27 7.9 NM NM NM NM NM NM
1107 Russia M/67 — 269 3.9 1.7 0.9 0.9 –1.7 2.5 2.0
1108 Russia F/70 Post 269 1.5 0.79 –0.9 –0.7 –2.9 –1.7 –2.1
1110 Australia F/57 Peri — 6.0 1.1 –0.1 3.3 1.9 0.6 0.4
1112 Australia F/53 Peri — 8.9 2.5 1.4 0.1 –1.0 1.7 1.7
1113 Sri Lanka M/57 — 220 3.2 –0.2 –0.8 1.5 –0.5 –0.2 –0.5
800 Australia F Post — 3.3 –0.01 –0.97 –2.3 –3.35 –0.98 –0.98
Abbreviations: F, female; M, male; NM, not measured (discontinued trial). for the three periods. Where there was no sig-
niﬁcant increase or decrease (p > 0.05) within
a period, a horizontal line was plotted through
the mean for each period for each subject. We
used analysis of variance (ANOVA) to com-
pare differences in average response between
periods for the perimenopausal group. For
comparisons within the perimenopausal
group, the analysis was repeated with male
subject 1101 omitted. Similar analysis could
not be performed on the postmenopausal
group because of small numbers of subjects in
different categories.
Results
Information about the subjects is provided in
Table 1 along with the subjects’ BPb concen-
trations at the first sampling and their bone
mineral densities. The statistical results from
the regression analyses of BPb concentration
and 206Pb/204Pb ratio for the three monitor-
ing periods are shown in Table 2, and the
ANOVA results are shown in Table 3.
To our knowledge, these are the ﬁrst lon-
gitudinal BPb measurements undertaken on
elderly subjects over an extended length of
time. For example, only two BPb measure-
ments 3 years apart were measured in the
Normative Aging Study (32), and only one
measurement was taken in the Swedish Twin
Registry (33). 
Hypothetical response for lead. Before
undertaking this study and using information
from earlier and ongoing studies, we predicted
the changes that could have been observed in
BPb isotopic composition and concentration
during alendronate therapy. The hypothetical
responses for menopausal migrant and multi-
generational Australian subjects are shown in
Figure 1. As six of the eight migrant subjects
had resided in Australia for more than 6
months, lead in the blood should have
reached a steady state between skeletal lead
and environmental (Australian) lead, similar
to that demonstrated earlier (5,6,28). During
administration of alendronate there should be
a decrease in the 206Pb/204Pb ratio (Figure 1;
or an increase in 207Pb/206Pb ratio) and possi-
bly a decrease in BPb concentration, assuming
this drug inhibits bone resorption. Such
changes would reflect a greater input to the
isotopic composition of exogenous Australian
lead such as diet, air, water, and house dust
lead compared with that from skeletal tissues.
A decrease in BPb concentration would reﬂect
a decrease in the amount of lead being
released from skeletal tissues to blood, rather
than any changes in excretion or clearance of
the lead from the blood (34). After cessation
of the treatment and a resumption of bone
resorption, the 206Pb/204Pb ratio and possibly
the BPb concentration should rise, reﬂecting
increased mobilization of lead from the skele-
ton (Figure 1). As the 206Pb/204Pb ratio in
multigenerational Australian subjects is less
than 17.1 and closer to 16.5 in older
Australians (35), there should be limited
changes in lead isotopic composition and BPb
concentration for the Australian subjects, with
a possible increase in 206Pb/204Pb ratio during
treatment and a decrease in 206Pb/204Pb ratio
after treatment. The BPb concentration could
be expected to decrease during treatment to
an extent related to the total skeletal lead bur-
den and the underlying rate of bone turnover.
Baseline monitoring for lead. The BPb
concentrations in the first sample obtained
from the migrant subjects ranged from 1.4 to
10.6 µg/dL (Table 1), surprisingly low given
the purported environmental contamination
in their country of origin and their relatively
long exposure to lead compared with current
levels. The highest values were for the
Bulgarian couple, who returned to Bulgaria
during the trial. The BPb concentrations at
the time of initial sampling for the three
Australian subjects ranged from 3.3 to 8.9
µg/dL (Table 1). These BPb concentrations
are generally below the level of concern of 10
µg/dL promulgated by the U.S. Centers for
Disease Control and Prevention (36). The
data for the baseline monthly measurements
(Figures 2 and 3) of BPb isotopic composition
and lead concentration exhibited a larger vari-
ation than we expected based on our previous
work. For example, there are only small varia-
tions for premenopausal migrant adult females
of child-bearing age who did not conceive in
the pregnancy study (Figures 4 and 5) (37) or
even pregnant subjects in our current preg-
nancy cohort who took calcium supplements
(38). The variations were largest in BPb con-
centration for subjects 1101, 1104, and 1110
and in isotopic composition for most subjects
except 1108 (Table 2; Figures 2 and 3).
Treatment period compared with pretreat-
ment period. Compared with the pretreatment
measurements, the data for the treatment
period showed consistent decreases in mean
levels for BPb isotopic composition and lead
concentration for most subjects (Table 2;
Figures 2 and 3). A significant decrease of
about 20% in average BPb concentration (p <
0.01) was observed for all migrant subjects
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Table 2. Statistical results for BPb concentration and 206Pb/204Pb from regression analyses.
Before treatment During treatment After treatmenta
Subject R2 p-Value R2 p-Value R2 p-Value
BPb concentration
1101 0.089 0.40 0.57 0.08 0.20 0.56
1102 0.38 0.10 0.58 0.08 0.08 0.71
1103 0.44 0.05 0.68 0.09 0.83 0.09
1104 0.10 0.34 0.35 0.29
1107 0.18 0.26 0.94 0.01 0.64 0.20
1108 0.60 0.04 0.56 0.05 0.25 0.50
1110 0.07 0.54 0.09 0.62 0.82 0.10
206Pb/204Pb
1101 0.11 0.34 0.30 0.26 0.59 0.23
1102 0.05 0.58 0.17 0.41 0.36 0.40
1103 0.06 0.52 0.92 0.01 0.28 0.47
1104 0.03 0.59 0.58 0.13
1107 0.14 0.32 0.88 0.02 0.73 0.15
1108 0.59 0.04 0.36 0.15 0.61 0.22
1110 0.00 0.99 0.58 0.13 0.96 0.02
aBecause sample size is based on 1 and 2 degrees of freedom, it is inadequate for signiﬁcance testing.
Table 3. Average response for the premenopausal group.
Response Before treatment During treatment After treatment
Blood Pb, all subjects (µg/dL) 2.14 1.74* 1.71 (NS)
Blood Pb, omitting subject 1101 1.83 1.46* 1.45 (NS)
206Pb/204Pb ratio, all subjects 17.67 17.57* 17.55 (NS)
206Pb/204Pb ratio, omitting subject 1101 17.73 17.62* 17.61 (NS)
207Pb/206Pb ratio, all subjects 0.8807 0.8850* 0.8860 (NS)
207Pb/206Pb ratio, omitting subject 1101 0.8777 0.8827* 0.8830 (NS)
NS, no signiﬁcant difference between during and after treatment. 
*Signiﬁcant difference between during and before treatment (p < 0.01). 
Figure 1. Predicted trends for changes in the
206Pb/204Pb ratio for a migrant subject and a long-
term Australian subject before alendronate treat-
ment, during treatment, and after treatment.
18.00
17.80
17.60
17.40
17.20
17.00
0 100 200 300 400 500 600 700 800
Days into recruitment
2
0
6
P
b
/
2
0
4
P
b
Background Treatment
Migrant
subject
Australian
subject(Tables 2 and 3). The 206Pb/204Pb ratio was
also signiﬁcantly reduced (p < 0.01). The same
results were obtained after omitting the male
subject 1101 from the analyses (Table 3). For
the three premenopausal female subjects
(1102, 1103, 1104), there was a decrease in
average 206Pb/204Pb ratio of about 0.6%, com-
pared with our measurement error of 0.2%
(e.g., Figure 4). Compared with the pre-
menopausal subjects, the female post-
menopausal migrant, subject 1108, exhibited a
slightly larger decrease in 206Pb/204Pb ratio of
up to 1.6% and a decrease of approximately
17% in BPb concentration during the treat-
ment phases relative to the pretreatment phase. 
The male subjects 1101 and 1107 exhib-
ited changes in 206Pb/204Pb ratio and BPb con-
centration similar to their partners, 1102 and
1108, respectively (Table 2; Figures 2 and 3).
Post-treatment. One of the pre-
menopausal subjects (1104) could not be fol-
lowed post-treatment because only one
sample was available. As mentioned above,
the hypothetical response post-treatment
should be an increase in the 206Pb/204Pb
ratio. In fact, an increase in 206Pb/204Pb ratio
occurred at different times depending on
menopausal status. For the premenopausal
subjects, the change in slope for increasing
206Pb/204Pb ratio occurred within approxi-
mately 60 days from cessation of treatment.
In contrast, the blood of the female post-
menopausal subject and her partner (1108,
1107) continued to exhibit a decrease in
206Pb/204Pb ratio post-treatment, and the
change in slope did not occur for more than
150 days of cessation of treatment. The
change in slope for the 206Pb/204Pb ratio was
apparent within 60 days of cessation of treat-
ment in the male subject (1113) who ceased
alendronate treatment after only 3 months
because of digestive complaints.
Australian subjects. Of the Australian sub-
jects, two were perimenopausal (subjects 1110
and 1112) and one (subject 800) was post-
menopausal (Table 1). The statistical results
for the Australian subjects 1112 and 800 have
not been listed because they showed exceed-
ingly large variations in lead isotopic compo-
sition and lead concentration (Figures 2 and
3). For subject 1110, there was a small increase
in the 206Pb/204Pb ratio but large ﬂuctuations
in the BPb concentration during the whole
trial (Table 2). The small decrease in the
206Pb/204Pb ratio post-treatment was expected
because this subject had relatively high BPb
concentrations, and analyses of her teeth gave a
low 206Pb/204Pb ratio of 16.5; teeth provide
evidence for the isotopic composition of the
skeleton (35). There were large ﬂuctuations in
isotopic composition for the postmenopausal
subject 800, who had been on HRT and alen-
dronate throughout the trial. Subject 1112
was undergoing HRT at the beginning of the
trial. At 184 days she discontinued the therapy
for 6 months. After she discontinued the ther-
apy, there was an increase in the 206Pb/204Pb
ratio in her blood and an increase of 25% in
BPb concentration, after which it returned to a
baseline level.
Bone density. We used the T-score and
Z-score to assess bone density. The T-score
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Figure 3. Time-series plots of BPb concentration for migrant subjects (1102, 1103, 1104, 1108, 1101, and
1107) and Australian subjects (800, 1110, and 1112) who underwent alendronate therapy.  Therapy began
on day 0, and cessation of therapy is represented by a break in the individual time lines. Premenopausal
subjects were 1102, 1103, 1104, and 1110; postmenopausal subjects were 1108, 1112, and 800; male sub-
jects were 1101 and 1107. Australian subject 800 was on HRT for the whole study. The BPb concentrations
were 5.1–11.1 µg/dL for subject 1110 and 7.1–13.4 µg/dL for subject 1112 and thus are not shown. 
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Figure 2. Time-series plots of 206Pb/204Pb ratios for migrant subjects (1102, 1103, 1104, 1108, 1101, and 1107)
and Australian subjects (800, 1110, and 1112) who underwent alendronate therapy. The therapy began at
day 0, and cessation of therapy is represented by a break in the individual time lines. Premenopausal sub-
jects were 1102, 1103, 1104, and 1110; postmenopausal subjects were 1108, 1112, and 800; male subjects
were 1101 and 1107. Australian subject 800 was on HRT for the whole study. 
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*describes how the measured bone density
compares with that of healthy young adults,
and the Z-score compares how the measured
bone density compares with the average of
persons of the same age as the subject being
tested. For a person with a low bone mass
(osteopenia) at the spine or hip, the T-score is
between –1 and –2.5; for normal bone mass,
the T-score is > –1; and for a subject with
osteoporosis, the T-score is ≤ –2.5. Overall,
the bone density results showed no signiﬁcant
differences for the 12-month period between
measurements, given that the precision of the
measurement of bone mineral density is
2–5%, although the changes for lumbar spine
are probably larger than for the wrist and
femoral neck. Subjects 1101, 1102, 1110, and
1112 had normal bone densities. Subjects
1103 and 1104 showed osteopenia in the
lumbar spine, with normal wrist and femoral
neck; subject 1107 showed osteopenia in the
femoral neck; subject 1108 showed osteo-
porosis in the wrist and femoral neck; and
subject 800 showed osteoporosis in the
femoral neck and osteopenia in the wrist.
Bone turnover indices. The most sensitive
biochemical tests we have that reﬂect changes
in bone resorption are measures of collagen
fragments as measured by the NTx assay. The
results are reported as a ratio with creatinine to
correct for variations in body mass between
individuals. In the female migrant subjects, per-
centage decreases in the NTx/creatinine ratio
during antiresorptive treatment relative to pre-
treatment varied from –16 to –60%, with
largest decrease for the postmenopausal subject
1108 (Figure 6). Decreases in the NTx/creati-
nine ratio were observed for the younger
migrant male (subject 1101), but there was an
unusual positive trend for the 67-year-old male
(subject 1107). Two Australian subjects, who
were on HRT before or throughout the study
(subjects 800, 1112), exhibited minimal
changes in the NTx/creatinine ratio. If only the
data for four migrant women are considered,
there is a strong correlation (Figure 7; R2 =
0.94, p = 0.03) between the percentage change
from pretreatment to treatment in NTx/creati-
nine ratio and the percentage change in the
lead isotopic ratios.
Lead in blood and initial BPb concen-
tration. Because there is a varying relation-
ship between lead in blood and lead in bone
(10,11,15,17), the cumulative total of lead in
blood over the pretreatment and treatment
phases was plotted against the BPb concentra-
tion at the time of ﬁrst sampling. There was a
significant correlation in these parameters
(Figure 8; p < 0.001), with the treatment
phase showing lower cumulative amounts of
lead in blood compared with the pretreat-
ment phase. This strong correlation contrasts
markedly with the scatter of data for the total
amount of lead in blood during pregnancy
and postpartum versus initial BPb concentra-
tion for women of child-bearing age (5,6).
The difference in the plots may be partly due
to the smaller range in BPb concentrations of
the pregnant subjects.
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Figure 4. Time-series plots of the 206Pb/204Pb ratio for nonpregnant female
adults who migrated to Australia. Values were relatively stable after equilib-
rium was reached between skeletal lead and environmental lead.
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Figure 5. Time-series plots of BPb concentration for nonpregnant female
adults who migrated to Australia. Values were relatively stable after equilib-
rium was reached between skeletal lead and environmental lead.
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Figure 6. NTx/creatinine ratio in subjects before, during, and after antiresorp-
tive therapy (alendronate). 
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Figure 7. Percentage change from pretreatment to treatment (Pre-Fos) in
NTx/creatinine ratio and the percentage change in lead isotopic ratios. This
ﬁgure suggests that the more bone response in terms of resorption, the more
the change in blood from the ﬂux of lead from the bone. 
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In spite of the variability in the data for each
subject, the decreases in the BPb concentra-
tion and the 206Pb/204Pb ratio during anti-
resorptive treatment followed the hypothetical
response. We observed these trends in the pre-
menopausal females (subjects 1102, 1103,
1104) as well as in the postmenopausal female
and her older male partner (subjects 1108,
1107). Even though the treatment period of 6
months was relatively short in this study, the
effect of the alendronate on bone resorption,
as shown by the increasing 206Pb/204Pb ratios
after treatment, appears to extend for several
months after cessation of treatment. The
change of increasing 206Pb/204Pb ratios for the
postmenopausal subject and her male partner
occurred later than for the premenopausal
subjects and may reﬂect prolonged efﬁcacy of
the alendronate therapy in the older subjects.
There was a good correlation for the changes
in NTx/creatinine ratio and changes in the
lead isotopic ratios for the four female migrant
subjects from the pretreatment to treatment
periods. The changes in BPb in both pre-
menopausal subjects and the postmenopausal
subject were consistent with decreased bone
resorption and associated mobilization of lead.
However, the expected decrease in BPb levels
during alendronate treatment should be more
pronounced in early postmenopausal women
with increased bone resorption relative to pre-
menopausal women.
The decrease in average BPb concentration
of the migrants of about 20% over the relatively
short period of treatment of 6 months is consid-
erably greater than changes observed in other
investigations of menopausal or elderly subjects
at the menopausal transition. For example,
Webber et al. (27) found that women taking
HRT over a 4-year period did not show a signif-
icant difference in BPb concentrations. The
authors suggested that HRT prevents the
menopause-associated increase in bone
turnover, such that lead would be expected to
remain in the skeleton. In contrast, in the
Mexico City study, Hernandez-Avila et al. (10)
found no difference in BPb concentrations
between postmenopausal women who used
estrogens and those who did not use them. In
spite of the changes in BPb concentration
observed in earlier studies (8–10), the relatively
large ﬂuctuations from serial BPb concentration
in our subjects indicate that single or cross-sec-
tional BPb measurements could be misleading
in terms of evaluating changes in bone turnover.
The variations observed in both isotopic
composition and BPb concentration for pre-
menopausal and postmenopausal subjects in
the study compared with the smooth trends
found in nonpregnant adult females 18–35
years of age (37) (Figures 4 and 5) are consid-
ered to reﬂect more extensive bone remodeling
in the older subjects and larger ﬂuctuations in
BPb concentration in particular. The signiﬁ-
cant relations between total lead in blood and
initial BPb concentration observed for the
elderly subjects (Figure 8) compared with the
scatter for pregnant subjects was, however,
unexpected and at this stage cannot be easily
explained.
It has been argued that the majority of
lead in blood of adults in steady state is skele-
tally derived, ranging from 42% to 75%
(5,29–31,39), with most evidence favoring the
upper end of this range. That is, exogenous
lead absorbed directly into the blood in real
time can be less than circulating lead from
bone release. However, both the data for the
migrant subjects and for Australian subjects
indicate that with suppression of bone resorp-
tion during alendronate treatment, diet and
other environmental exposures may play an
increased role in BPb, perhaps complemented
by decreased calcium absorption associated
with aging. It is well established that calcium
inhibits uptake of lead from the gastrointesti-
nal tract (40,41). Heaney et al. (42) have
shown there is a gradual decrease in calcium
absorption from age 35 onward, accompanied
by an additional one-time decrease across
menopause. Decreased calcium absorption
may explain an increased lead absorption in
the elderly. Instead of increased lead absorp-
tion from diet during the treatment period, an
alternative explanation for the changes in lead
isotopic composition and BPb concentrations
may reflect contributions from the different
bone compartments with their different rates
of turnover of lead and exchange of lead and
calcium between bone compartments and the
blood/serum compartment (43,44). Lead and
calcium on bone surfaces are thought to be
exchanged rapidly with those metals circulat-
ing in serum and blood, whereas the exchange
between the bone interior and bone surface is
considerably slower (43,44). As the most
recently deposited (periosteal) lead should be
that with a dominant Australian isotopic com-
position, there should be a decrease in the
206Pb/204Pb ratio.
The low BPb concentrations in the
migrant subjects, especially from Eastern
Europe, were surprising given the purported
environmental contamination in many of
these countries and hence potential long-term
lead exposure for the subjects resulting in
high bone-lead stores. One explanation for
the low BPb concentrations is that any earlier
high lead concentrations have been flushed
from the blood compartment, as the subjects
had been in Australia for more than 9
months. Gulson et al. (29) showed that
higher BPb concentrations in migrant sub-
jects decrease exponentially after arrival in
Australia, and an equilibrium or steady state
in BPb concentration (and isotopic composi-
tion) in the migrants is reached about 4–6
months after arrival in Australia. For exam-
ple, the BPb concentration in one subject
decreased from 20 µg/dL on arrival to about
6 µg/dL after 6 months, although the lead
isotopic composition indicated that approxi-
mately 70% of the lead in blood was skele-
tally derived. In spite of current relatively low
BPb concentrations, our subjects could still
have high bone-lead stores, available for extra
release during periods of physiologic stress
such as menopause. If the subjects had high
bone-lead stores, one might expect a rebound
to higher BPb concentrations once treatment
with alendronate had ceased, similar to the
increases in skeletally derived lead observed in
the pregnancy study (5,6). In fact, we did not
observe this, as the BPb concentrations were
lower after treatment than before treatment
(Table 3); because the after-treatment moni-
toring period was relatively short, it is possi-
ble that the lower BPb concentrations may
reﬂect ongoing efﬁcacy of the alendronate. 
There appears to be a difference in the vari-
ability in BPb isotopic composition and con-
centration in the period before treatment and
during treatment, as shown in Figures 2 and 3
and in the results of the regression analyses.
This difference is superimposed on the decreas-
ing lead isotopic ratios and lead concentrations
during the treatment period for most of the
subjects. For example, there is signiﬁcant vari-
ability in the before-treatment phase where R2
values in both BPb concentration and isotopic
composition are low and only reach 0.6 for
subject 1108 (Table 2). In contrast, apart from
the Australian perimenopausal subject 1110,
the R2 values during the treatment phase are
commonly above 0.5. Is this apparent stability
in BPb during the treatment phase, although
decreasing, related to the alendronate therapy?
Such a hypothesis requires follow-up in a larger
and longer term study.
There are a number of potential limita-
tions to this study. The small number of
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Figure 8. Total amount of lead in blood in the pre-
treatment and treatment phases compared with
the BPb concentration at the time of ﬁrst sampling.
The significant correlation (p < 0.001) compared
with the scatter observed for pregnant migrant
subjects may reflect a higher bone store in the
elderly. For linear (treatment), R2 = 0.9554, p < 0.001.
For linear (pretreatment), R2 = 0.9743, p < 0.001. 
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1103subjects was exacerbated by withdrawal of sev-
eral participants for reasons unrelated to the
study protocols. Also, the treatment period of
6 months is only about 70% of the full miner-
alization period of about 40 weeks (20,45).
However, this study remains the most exten-
sive to date of the effect of antiresorptive
agents on BPb concentrations that apparently
arise from bone sources. Given the association
of BPb levels with potential adverse health
outcomes, such as hypertension and dementia,
administration of potent antiresorptive drugs
such as alendronate to postmenopausal
women and older men and women could have
additional public health beneﬁts, besides low-
ering the incidence of fractures in both
females and males. The potential effect on
other health parameters of antiresorptive
agents requires further evaluation. A larger
study would allow a quantitative estimate of
how much bone remodeling is suppressed by
agents such as the bisphosphonates.
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